RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jan. 30, 2006--Icagen, Inc. (NASDAQ: ICGN) today announced that, following the first per protocol interim safety review, an independent data monitoring committee (“DMC”) recommended that Icagen continue its pivotal Phase III clinical trial of ICA-17043 for the treatment of sickle cell disease as planned. The DMC meets approximately every six months to review unblinded safety data from the pivotal Phase III clinical trial.
